Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery
Active, not recruitingPhase 4NCT06374849
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Several risk factors for chronic postoperative pain have been identified. A series of studies have shown that administrating intraoperatively a high dose of Remifentanil is associated with an increased incidence of CPSP. These findings highlight a risk factor for CPSP that the anaesthetist can influence on, but they however remain limited to remifentanil. To this day, no study have attempted to evaluate the existence of such an association between the incidence of CPSP and the intraoperative administration of sufentanil doses. Improved knowledge of the long-term nociceptive impact of intraoperative sufentanil administration would enable better therapeutic adaptation according to each patient's risk. In the field of CPSP, non-major abdominal surgeries remain poorly studied. This is due to their lower risk of CPSP than other surgeries such as orthopaedic, mammary or thoracic surgery. Nevertheless, they constitute a large number of daily surgical procedures. The estimated incidence of CPSP in non-major abdominal surgery appears in several studies to be between 15 and 20% The aim of this study is to evaluate the correlation between the intraoperative administration of sufentanil doses and the incidence of CPSP at 3 months in patients undergoing non-major scheduled abdominal surgery.
Study details
- Official title
- Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery
- Conditions
- Chronic Postsurgical Pain
- Chronic Pain
- Abdominal Surgery
- Sufentanil
- Risk Factors
- Interventions
- Other: phone interview
- Sponsor
- Centre Hospitalier Universitaire, Amiens
- Start date
- 2024-06-24
- Primary completion
- 2025-04-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age \> 18 years old. * Non-major scheduled abdominal surgery. * Patient will receive Sufentanil intraoperatively for induction and maintenance of general anesthesia * Written or oral informed consent to participate in the study. Exclusion Criteria: * Intraoperative complications that are life-threatening or require the surgical procedure to be discontinued. * Repeat surgery at the same surgical site in less than 3 months. * Pregnancy. * Ambulatory surgery. * Endoscopic surgery. * Surgery with loco-regional or perimedullary anesthesia without general anesthesia * Intraoperative use of an opioid other than Sufentanil. * Hypersensitivity to sufentanil * Legally protected patients (under judicial protection, guardianship, curatorship). * Patients suffering from psychiatric pathologies. * Patients suffering from neurodegenerative pathologies. * Patients for whom self-assessment of pain using an numerical rating scale (0-10) is not feasible (language barrier, etc…)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06374849